TrialThe Journal of infectious diseases2011

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Grace A McComsey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.